Targeting metastatic cancer
K Ganesh, J Massague - Nature medicine, 2021 - nature.com
Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …
cause of cancer death. Recent work has uncovered the unique biology of metastasis …
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …
The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …
A Marabelle, M Fakih, J Lopez, M Shah… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of …
response to immune checkpoint blockade. We prospectively explored the association of …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
[HTML][HTML] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - Elsevier
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
[HTML][HTML] First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial
LG Paz-Ares, SS Ramalingam, TE Ciuleanu… - Journal of Thoracic …, 2022 - Elsevier
Abstract Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
Beyond immune checkpoint blockade: emerging immunological strategies
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
mosaic of single agents and combination immunotherapies. However, the lack of clinical …